High Risk WHO Grade II Glioma
1 clinical trials · Condition
◉ Watch High Risk WHO Grade II Glioma
| Record | Firm | Date |
|---|---|---|
| Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas (NCT01678352) | Frank Lieberman | 2012-10-01 |
Track High Risk WHO Grade II Glioma automatically
Every clearance here is in the API, with alerts when new ones post.